* X4 Pharmaceuticals Inc reported a quarterly adjusted loss of 18 cents per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -1 cents. The mean expectation of seven analysts for the quarter was for a loss of 17 cents per share. Wall Street expected results to range from -19 cents to -15 cents per share.
* Revenue was $560.00 thousand; analysts expected $1.69 million.
* X4 Pharmaceuticals Inc's reported EPS for the quarter was a loss of 18 cents.
* The company reported a quarterly loss of $36.7 million.
* X4 Pharmaceuticals Inc shares had fallen by 11.5% this quarter and lost 29.4% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts was unchanged in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for X4 Pharmaceuticals Inc is 5.00 This summary was machine generated from LSEG data November 13 at 03:27 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.17 -0.18 Missed
Jun. 30 2024 0.01 -0.07 Missed
Mar. 31 2024 -0.16 -0.26 Missed
Dec. 31 2023 -0.15 -0.10 Beat
Comments